Fluorodeoxyglucose Positron Emission Tomography Can Provide Useful Information for Differentiating Thymic Epithelial Tumors
28 February 2017
02 June 2017
20 July 2017 (eFirst)
Background We examined the usefulness of fluorodeoxyglucose (FDG) positron emission tomography (PET) in predicting the World Health Organization (WHO) histologic type and Masaoka stage of thymic epithelial tumors.
Methods A total of 73 patients with thymic epithelial tumors who underwent preoperative FDG-PET were included. Relationships between the maximum standardized uptake value (SUVmax) and WHO histologic type and the Masaoka stage of the tumor were examined. Differences in SUVmax between the various groups were calculated. To avoid the effect of the tumor size on SUVmax, the ratio of SUVmax to tumor size (SUVmax/T) was also examined.
Results There was a significant relationship between SUVmax and WHO histologic type. SUVmax of high-risk thymomas (types B2 and B3) was significantly higher than that of low-risk thymomas (types A, AB, and B1). SUVmax of thymic carcinomas was also significantly higher than those of the low-risk and high-risk groups. The relationship between the SUVmax/T and WHO histologic type showed more significant results. SUVmax and SUVmax/T showed higher values in patients with advanced Masaoka stage disease than in those with early-stage disease.
Conclusions FDG-PET can provide useful information for differentiating thymic epithelial tumors. The SUVmax/T is more useful than the SUVmax for differentiating between low-risk and high-risk thymomas.
- 1 Travis WD, Brambilla E, Mueller-Hermelink HK, Harris CC. WHO Classification of Tumors. Pathology and Genetics of Tumors of the Lung, Pleura Thymus and Heart. Lyon, France: IARC Press; 2004
- 2 Kondo K, Yoshizawa K, Tsuyuguchi M. , et al. WHO histologic classification is a prognostic indicator in thymoma. Ann Thorac Surg 2004; 77 (04) 1183-1188
- 3 Chen G, Marx A, Chen WH. , et al. New WHO histologic classification predicts prognosis of thymic epithelial tumors: a clinicopathologic study of 200 thymoma cases from China. Cancer 2002; 95 (02) 420-429
- 4 Liu Y. Characterization of thymic lesions with F-18 FDG PET-CT: an emphasis on epithelial tumors. Nucl Med Commun 2011; 32 (07) 554-562
- 5 Treglia G, Spitilli MG, Calcagni ML, Giordano A. The role of nuclear medicine in the management of thymomas. Ann Ital Chir 2007; 78 (05) 371-374
- 6 Lococo F, Cesario A, Okami J. , et al. Role of combined 18F-FDG-PET/CT for predicting the WHO malignancy grade of thymic epithelial tumors: a multicenter analysis. Lung Cancer 2013; 82 (02) 245-251
- 7 Treglia G, Sadeghi R, Giovanella L, Cafarotti S, Filosso P, Lococo F. Is (18)F-FDG PET useful in predicting the WHO grade of malignancy in thymic epithelial tumors? A meta-analysis. Lung Cancer 2014; 86 (01) 5-13
- 8 Matsumoto I, Oda M, Takizawa M. , et al. Usefulness of fluorine-18 fluorodeoxyglucose-positron emission tomography in management strategy for thymic epithelial tumors. Ann Thorac Surg 2013; 95 (01) 305-310
- 9 Benveniste MF, Moran CA, Mawlawi O. , et al. FDG PET-CT aids in the preoperative assessment of patients with newly diagnosed thymic epithelial malignancies. J Thorac Oncol 2013; 8 (04) 502-510
- 10 Thomas A, Mena E, Kurdziel K. , et al. 18F-fluorodeoxyglucose positron emission tomography in the management of patients with thymic epithelial tumors. Clin Cancer Res 2013; 19 (06) 1487-1493
- 11 Kaira K, Murakami H, Miura S. , et al. 18F-FDG uptake on PET helps predict outcome and response after treatment in unresectable thymic epithelial tumors. Ann Nucl Med 2011; 25 (04) 247-253
- 12 Seki N, Sakamoto S, Karube Y, Oyaizu T, Ishihama H, Chida M. 18F-fluorodeoxyglucose positron emission tomography for evaluation of thymic epithelial tumors: utility for World Health Organization classification and predicting recurrence-free survival. Ann Nucl Med 2014; 28 (03) 257-262